SKYEHealthcare · BiotechnologyThe 4 Wall Street analysts covering Skye Bioscience, Inc. hold a median 12-month price target of $48 — +2312.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 14 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Skye Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SKYE, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +2312.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2025 | HC Wainwright & Co. | Initiates | Buy | $20 |
| 15 Aug 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 24 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 21 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 21 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 28 Feb 2025 | William Blair | Initiates | Outperform | — |
| 30 Sept 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Piper Sandler | Reiterates | Overweight | — |
| 10 Sept 2024 | JMP Securities | Initiates | Market Outperform | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 July 2024 | Craig-Hallum | Initiates | Buy | — |
| 1 July 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 17 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 23 May 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 Apr 2024 | Oppenheimer | Initiates | Outperform | — |
| 14 Mar 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SKYE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 99% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Skye Bioscience, Inc. has a market value of $9.0M and an enterprise value of −$853K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$50.5M.
Diluted earnings per share, trailing twelve months: $−1.27.
Free cash flow in the twelve months to 30 June 2026: −$38.8M.
Trailing P/E: 3.6×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Skye Bioscience, Inc. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Skye Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Skye Bioscience, Inc. (SKYE) held an M&A call, and Seeking Alpha published the prepared remarks transcript from the event.
Why it matters — SKYE watchers would care because the M&A call transcript provides direct insight into the company's strategic rationale behind its merger and acquisition activities.
Skye Bioscience and privately-held Redx Pharma announced a definitive transaction agreement to combine, with the combined company to trade on Nasdaq as Fibrx Therapeutics, led by Redx's management team and board. A syndicate of institutional investors committed approximately $125 million in aggregate financings, expected to fund operations through the lead program RXC008's Phase 2 clinical trial, with topline data expected in H2 2028.
Why it matters — SKYE watchers would care because the transaction substantially changes the company's identity and pipeline, refocusing it as a fibrosis-focused firm under Redx management with new financing to support the RXC008 Phase 2 program.
The 4 Wall Street analysts covering Skye Bioscience, Inc. have a median 12-month price target of $48, with estimates ranging from $16 to $160. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Skye Bioscience, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Skye Bioscience, Inc. 36 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, Skye Bioscience, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +2312.1% from the last close, and Ticker Nerd's factor model ranks Skye Bioscience, Inc. 36 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Skye Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SKYE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $160 over the next 12 months.
Skye Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies that modulate the endocannabinoid system, with an emphasis on metabolic health and obesity-related conditions.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript". Skye Bioscience, Inc. (SKYE) held an M&A call, and Seeking Alpha published the prepared remarks transcript from the event.
Skye Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies that modulate the endocannabinoid system, with an emphasis on metabolic health and obesity-related conditions. Its current pipeline centers on nimacimab, a peripherally restricted antibody targeting cannabinoid receptor 1, designed to influence pathways involved in fat mobilization, appetite regulation, satiety signaling, and broader metabolic function. The company also develops ophthalmic programs, including SBI-100 Ophthalmic Emulsion, for eye diseases such as glaucoma and ocular hypertension. Skye Bioscience works across areas including obesity, overweight, metabolic disorders, and select ophthalmology applications, positioning its research around GPCR-based drug development and cannabinoid receptor biology. Headquartered in San Diego, California, Skye Bioscience Inc. operates as a focused biopharmaceutical company advancing targeted, mechanism-based candidates for currently addressed therapeutic markets.
CEO Mr. Punit S. Dhillon B.A. · 2 employees · United States · https://skyebioscience.com